Divisions of General Surgery and Mayo Clinic, Jacksonville, Florida, USA.
Divisions of Anesthesiology, Mayo Clinic, Jacksonville, Florida, USA.
J Laparoendosc Adv Surg Tech A. 2022 Feb;32(2):176-182. doi: 10.1089/lap.2020.0783. Epub 2021 May 14.
Enhanced recovery after surgery (ERAS) pathways focus on decreasing surgical stress and promoting return to normal function for patients undergoing surgical procedures. The aim of our study was to evaluate the impact of an ERAS protocol on outcomes of patients undergoing primary sleeve gastrectomy and Roux-en-Y gastric bypass. Outcomes included hospital length of stay (LOS), and management of postoperative pain and postoperative nausea and vomiting (PONV) measured by pain medications and antiemetic use, respectively. Incidence of 90-day emergency department (ED) visits, readmissions, and complications were also analyzed. A retrospective review was performed from October 1, 2016 to October 31, 2018 of patients enrolled in the ERAS versus the conventional pathway. Patient baseline characteristics, pain and nausea scores, LOS, and postoperative outcome variables were collected. Non-ERAS ( = 193) and ERAS ( = 173) groups had similar patient characteristics. Fewer ERAS patients required postoperative opioids and antiemetics ( < .01), with a significant difference in postoperative nausea control in favor of ERAS patients ( < .05). There was a decreasing trend in median LOS (2 versus 1, = .28), 90-day postoperative readmissions (10.4% versus 8.1%, = .47), and major adverse events (5.2% versus 1.7%, = .07) after ERAS implementation. The ED visits and postoperative need for intravenous fluid for dehydration were significantly lower in the ERAS group ( = .01). Implementation of ERAS pathway for bariatric surgery was associated with less opioid usage, PONV, ED visits, and postoperative need for intravenous fluids, without increasing LOS, 90-day readmission or rates of adverse effects.
术后加速康复(ERAS)路径专注于降低手术应激,促进接受手术的患者恢复正常功能。我们的研究目的是评估 ERAS 方案对接受袖状胃切除术和 Roux-en-Y 胃旁路术的患者的治疗效果。结果包括住院时间(LOS),术后疼痛和术后恶心呕吐(PONV)的管理,分别通过疼痛药物和止吐药的使用来衡量。还分析了 90 天内急诊(ED)就诊、再入院和并发症的发生率。对 2016 年 10 月 1 日至 2018 年 10 月 31 日期间参加 ERAS 与常规治疗的患者进行了回顾性研究。收集了患者的基线特征、疼痛和恶心评分、LOS 以及术后结果变量。非 ERAS(n=193)和 ERAS(n=173)组患者的特征相似。ERAS 组患者术后需要使用阿片类药物和止吐药的比例较少( < .01),且在控制术后恶心方面明显优于 ERAS 组( < .05)。与 ERAS 实施前相比,LOS 的中位数呈下降趋势(2 天与 1 天, = .28),90 天术后再入院率(10.4%与 8.1%, = .47)和主要不良事件(5.2%与 1.7%, = .07)有所下降。ERAS 组 ED 就诊和术后因脱水需要静脉补液的情况明显较少( = .01)。肥胖症手术中实施 ERAS 路径与减少阿片类药物使用、PONV、ED 就诊和术后静脉补液的需求相关,而不会增加 LOS、90 天再入院或不良事件的发生率。